Acquisition | GRACELL BIOTECHNOLOGIES INC | 22nd February 2024

Initially announced on December 26, 2023 ASTRAZENECA PLC-SPONS ADR made a cash offer for GRACELL BIOTECHNOLOGIES INC of USD 10 and 1 CVR per GRACELL BIOTECHNOLOGIES INC share held. At a special meeting held on February 20, 2024, shareholders of GRACELL BIOTECHNOLOGIES INC approved the proposed merger with ASTRAZENECA PLC-SPONS ADR. Pending the completion of customary closing conditions, the Acquisition is expected to be completed on February 22, 2024. Trading in shares of GRACELL BIOTECHNOLOGIES INC is expected to be halted effective February 22, 2024. Due to the presence of a CVR in the offer, THESEUS PHARMACEUTICALS INC will be removed at its last close price effective (open) February 22, 2024.

The treatment below will be applied to the following indices:

• GRACELL BIOTECHNOLOGIES INC will be removed from the Index.
• The weight of GRACELL BIOTECHNOLOGIES INC (GRCL.OQ) based on its last close price will be distributed pro rata to remaining Index constituents.
• Effective Date (open): 22/02/2024

Solactive Gene Technology & Innovative Medication Index NTR
Solactive Gene Technology & Innovative Medication Index PR
Solactive Gene Technology & Innovative Medication Index GTR
Solactive United States Biotechnology Index NTR
Solactive United States Biotechnology Index PR
Solactive United States Biotechnology Index TR
Solactive US Extended Broad Market Index (GTR)